Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JAIME P ALMANDOZ

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1215060876
CMS profile
995913
Location
DALLAS, TX

General Payments · PY2018–2024

$138,856.70

  • Reported across 149 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$65,182.34

48 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $34,239.50 11
Novo Nordisk AS $17,122.73 15
Boehringer Ingelheim Pharmaceuticals, Inc. $12,477.52 19
ABBVIE INC. $1,162.50 1
Lilly USA, LLC $180.09 2

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $21.07 1
PY2019 $514.94 13
PY2020 $127.25 3
PY2021 $144.21 4
PY2022 $34,048.86 46
PY2023 $38,818.03 34
PY2024 $65,182.34 48

Payment records · PY2024 (48)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $1,162.50 12/06/2024 Consulting Fee Undisputed 01/23/2026 1103131379 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $424.17 02/01/2024 Travel and Lodging Undisputed 01/23/2026 1117917269 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $57.36 02/29/2024 Travel and Lodging Undisputed 01/23/2026 1117917253 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $212.40 03/11/2024 Travel and Lodging Undisputed 01/23/2026 1117917259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.00 04/05/2024 Food and Beverage Undisputed 01/23/2026 1117917245 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 04/05/2024 Travel and Lodging Undisputed 01/23/2026 1117917257 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9,000.00 04/05/2024 Consulting Fee Undisputed 01/23/2026 1117917275 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.98 04/18/2024 Food and Beverage Undisputed 01/23/2026 1117917241 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.98 04/18/2024 Food and Beverage Undisputed 01/23/2026 1117917243 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $39.99 04/18/2024 Food and Beverage Undisputed 01/23/2026 1117917247 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $39.99 04/18/2024 Food and Beverage Undisputed 01/23/2026 1117917249 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $100.48 04/18/2024 Food and Beverage Undisputed 01/23/2026 1117917255 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $352.33 04/18/2024 Travel and Lodging Undisputed 01/23/2026 1117917267 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $577.11 11/08/2024 Travel and Lodging Undisputed 01/23/2026 1117917271 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $30.07 12/10/2024 Food and Beverage Undisputed 01/23/2026 1117917239 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $47.81 12/10/2024 Food and Beverage Undisputed 01/23/2026 1117917251 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $302.56 12/10/2024 Travel and Lodging Undisputed 01/23/2026 1117917265 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $597.41 12/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1117917273 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $223.44 12/16/2024 Travel and Lodging Undisputed 01/23/2026 1117917261 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $233.44 12/16/2024 Travel and Lodging Undisputed 01/23/2026 1117917263 CMS
Eli Lilly and Company $9,277.00 02/23/2024 Travel and Lodging Undisputed 01/23/2026 1134990244 CMS
Eli Lilly and Company $6,950.00 02/27/2024 Consulting Fee Undisputed 01/23/2026 1135017384 CMS
Eli Lilly and Company $2,750.00 05/22/2024 Consulting Fee Undisputed 01/23/2026 1135040473 CMS
Eli Lilly and Company $2,750.00 06/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135034392 CMS
Eli Lilly and Company $825.00 06/11/2024 Consulting Fee Undisputed 01/23/2026 1135035590 CMS
Eli Lilly and Company $1,650.00 07/26/2024 Consulting Fee Undisputed 01/23/2026 1135034390 CMS
Eli Lilly and Company $2,750.00 09/26/2024 Consulting Fee Undisputed 01/23/2026 1135016710 CMS
Eli Lilly and Company $2,612.50 10/22/2024 Consulting Fee Undisputed 01/23/2026 1135041585 CMS
Eli Lilly and Company $2,750.00 11/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135017386 CMS
Eli Lilly and Company $550.00 12/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135035592 CMS
Eli Lilly and Company $1,375.00 12/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135040471 CMS
Lilly USA, LLC $91.59 03/14/2024 Food and Beverage Undisputed 01/23/2026 1135034394 CMS
Lilly USA, LLC $88.50 11/04/2024 Food and Beverage Undisputed 01/23/2026 1134990246 CMS
Novo Nordisk Inc $900.00 01/01/2024 Consulting Fee Undisputed 01/23/2026 1096608384 CMS
Novo Nordisk Inc $67.88 05/02/2024 Food and Beverage Undisputed 01/23/2026 1096826703 CMS
Novo Nordisk Inc $67.55 06/12/2024 Food and Beverage Undisputed 01/23/2026 1097169294 CMS
Novo Nordisk Inc $1,575.00 06/17/2024 Consulting Fee Undisputed 01/23/2026 1097693226 CMS
Novo Nordisk Inc $89.37 06/23/2024 Food and Beverage Undisputed 01/23/2026 1096673288 CMS
Novo Nordisk Inc $32.27 07/25/2024 Education Undisputed 01/23/2026 1096764578 CMS
Novo Nordisk Inc $900.00 08/27/2024 Consulting Fee Undisputed 01/23/2026 1096812965 CMS
Novo Nordisk Inc $900.00 08/27/2024 Consulting Fee Undisputed 01/23/2026 1097623686 CMS
Novo Nordisk Inc $42.61 11/05/2024 Food and Beverage Undisputed 01/23/2026 1097707328 CMS
Novo Nordisk Inc $1,350.00 11/12/2024 Consulting Fee Undisputed 01/23/2026 1097499047 CMS
Novo Nordisk Inc $653.14 11/13/2024 Travel and Lodging Undisputed 01/23/2026 1096633660 CMS
Novo Nordisk Inc $383.28 11/13/2024 Food and Beverage Undisputed 01/23/2026 1097086670 CMS
Novo Nordisk Inc $566.17 11/13/2024 Travel and Lodging Undisputed 01/23/2026 1097121934 CMS
Novo Nordisk Inc $932.96 11/13/2024 Travel and Lodging Undisputed 01/23/2026 1097498661 CMS
Novo Nordisk Inc $8,662.50 11/13/2024 Consulting Fee Undisputed 01/23/2026 1097693471 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.